Introduction
Adiponectin of molecular mass 28 kDa is a member of the adipocytokines, and it is secreted exclusively by mature adipocytes. 1 Biologically speaking, adiponectin possesses a well-defined set of properties, including insulin sensitization, anti-inflammation, anti-atherosclerosis, proapoptosis and antiproliferation. 2, 3 In circulation, adiponectin exists in forms of trimer, hexamer and high-molecular weight (HMW) complex, and these fractions are proven to have different biological activities. 4 For example, HMW adiponectin has a close relationship to insulin sensitivity, while the relevance between non-HMW adiponectin and anti-inflammation is more obvious.
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Mounting evidence from human studies reveal that low total adiponectin in circulation represents a predisposing status for development of colorectal cancer. [6] [7] [8] By contrast, other researchers failed to confirm this claim, [9] [10] [11] and some of them even found a higher concentration of circulating total adiponectin in patients with colorectal cancer than in controls. 12, 13 Several systematic reviews and meta-analyses have summarized published data involving the association between circulating total adiponectin and colorectal cancer risk, [14] [15] [16] [17] [18] [19] [20] while interpretation of pooled findings in most cases is clouded by the presence of substantial heterogeneity and none considered adiponectin fractions as separate factors. With growing epidemiological data, our understanding on circulating adiponectin and its fractions and colorectal cancer needs replenishment and renewal. Hence, the principal goal of the present study is to test the hypothesis that circulating total adiponectin or certain fractions may represent a promising biological candidate in modulating the risk of colorectal cancer, assessed through a comprehensive meta-analysis. A secondary goal is to explore possible sources of heterogeneity of effect size across studies through both subgroup analysis and meta-regression analysis.
Methods guideline
The present study was carried out in strict accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. 21 
Paper identification
Potentially eligible papers were identified through searching public databases of MEDLINE (PubMed), EMBASE, Web of Knowledge and Scholar (Google). All identified papers from each database were merged together and then duplicates removed. The key items used for paper identification included ("colorectal" or "colon" or "rectal") in title and ("cancer" or "carcinoma" or "tumor" or "tumour" or "neoplasm" or "adenoma") in title and ("adiponectin" or "adipocytokine" or "adipokine") in title/abstract. The process of paper identification was completed independently and in duplicate (Weiqun Lu and Zhiliang Huang) using the same key items mentioned above.
eligibility criteria
Eligibility criteria consisted of both inclusion criteria and exclusion criteria. Papers were included only when the following conditions were met simultaneously: (i) publication using the English language; (ii) either cross-sectional or nested case-control study design; (iii) involvement of only human beings; and (iv) availability of circulating plasma or serum adiponectin concentration for patients with colorectal or colon or rectal cancer and cancer-free controls. Papers were excluded when any of the following conditions was true: (i) non-original contribution; (ii) narrative or systematic review or meta-analysis; (iii) conference abstract; and (iv) case report or case series.
Paper selection
Two authors (Weiqun Lu and Zhiliang Huang) selected the papers that met the above inclusion criteria through reviewing the title or abstract or the full text, if necessary, of each identified article. When disagreement happened during the selection process, it was resolved by discussion or seeking help from the third author (Haiying Liu).
Data extraction
From each qualified paper, data for analysis including, if available, the first author's name, publication year, country where the study was conducted, study design, cancer subtype, matching status, source of controls, selection of controls, sample size, assay method for circulating adiponectin, sample type, age, gender, body mass index (BMI), waist-hip ratio (WHR), waist circumference, physical activity, physical inactivity, smoking habit, family history, diabetes mellitus, glucose, insulin, C-reactive protein (CRP) and adiponectin were extracted and entered into databases by two authors (Weiqun Lu and Zhiliang Huang). Extracted data were compared, and disagreement was resolved through consensus and discussion.
statistical analysis
Data were statistically analyzed by the Stata/SE software version 14.0 (StataCorp LP, College Station, TX, USA). Weighted mean difference (WMD) was adopted to assess the difference in circulating adiponectin concentration between patients and controls in both overall and subgroup analyses, and its 95% confidence interval (95% CI) was estimated accordingly under the random-effects model based on the DerSimonian-Laird method. Heterogeneity was first evaluated with the I 2 statistic, and then was explored through both subgroup and meta-regression analyses. The I 2 statistic is expressed as a percentage figure, and the higher the figure, the more likely the heterogeneity becomes. It is widely accepted the significance cutoff point of I 2 statistic is set at 50%. Publication bias was assessed by the Begg's funnel plot, filled funnel plot and Egger's regression asymmetry test.
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adiponectin and colorectal cancer: a meta-analysis The Egger's regression asymmetry test records significance if the probability value is ,10%.
Results
Qualified studies
A total of 339 papers were identified through searching public databases, and 295 of them were excluded after reading the title and abstract. Further, after full-text reviewing, 13 papers were excluded as they failed to meet our predefined inclusion criteria, leaving 31 eligible papers for meta-analysis in this study. [5] [6] [7] [8] [9] [10] [11] [12] [13] Thereof, 16 papers provided data by cancer type, gender or race, and so there were 48 qualified studies. study characteristics Table 1 shows the baseline characteristics of all qualified studies. After removing shared controls, this metaanalysis involved 7,554 patients with colorectal cancer and 9,798 controls. Of 48 qualified studies, only one study focused on HMW adiponectin. 39 In addition, eight studies also measured HMW adiponectin, and non-HMW adiponectin was recorded in six studies.
Overall analysis
Overall analysis was based on 41 qualified studies, and the funnel plot illustrating the difference in total adiponectin concentrations between patients with colorectal cancer and controls is presented in Figure 1 . Pooling effect size of all studies found that total adiponectin was significantly lower in patients with colorectal cancer than in controls (WMD: -0.76 µg/mL, 95% CI: -1.20 to -0.32, p=0.001). However, this significant finding was clouded by strong evidence of statistical heterogeneity (I 2 : 94.2%, p,0.001). Figure 2 shows another funnel plot quantifying the differences in adiponectin fractions -HMW adiponectin and non-HMW adiponectin -between patients with colorectal cancer and controls. The difference in HMW adiponectin was comparable between the two groups (WMD: -0.22 µg/mL, 95% CI: -0.70 to 0. 25 By sample size, grouping studies by median total sample size showed that the reduction of total adiponectin was obvious in studies with total sample size .230 (WMD: -0.271 µg/mL, p,0.001), and the likelihood of heterogeneity was low (I 2 : 12.1%). By gender, total adiponectin was reduced significantly in male patients relative to male controls (WMD: -0.671 µg/mL, p=0.025) (I 2 : 90.4%), and there was no observable significance in females.
By obesity, studies were grouped by mean or median BMI at 25 kg/m 2 , and significant reduction in total adiponectin was noted in both groups, especially in studies with BMI ,25 kg/m 2 (WMD: -1.627 µg/mL, p=0.029) (I 2 : 92.1%). In addition, when studies were grouped by mean or median WHR at 0.9 m, there was significant reduction in studies with WHR $0.9 m (WMD: -0.522 µg/mL, p=0.014).
After restricting to studies involving subjects free of diabetes mellitus, the reduction in total adiponectin was not statistically significant, and there was significant heterogeneity. By tumor node metastasis stage, the reduction in magnitude of total adiponectin was slightly stronger in patients with stage I-II colorectal cancer (WMD: -1.280 µg/mL, p=0.003) than in patients with stage III-IV cancer (WMD: -1.196 µg/mL, p=0.005), and significance was detected in both subgroups with significant heterogeneity but a low probability of publication bias. Table 3 lists the results of meta-regression analysis by incorporating all characteristics to assess whether they can explain the heterogeneity between total adiponectin and colorectal cancer. Age and smoking in both patients and controls were significant potential sources of heterogeneity, and BMI, waist circumference and CRP can account for heterogeneity only in patients ( p,0.05).
Meta-regression analysis
Publication bias
Overall comparison of total adiponectin between patients with colorectal cancer and controls was not subject to publication bias, which was illustrated by both Begg's and filled funnel plots in Figure 3 , as well as by the Egger's regression asymmetry test ( p=0.336). For comparisons in subgroup analysis, there was consistently low likelihood of publication bias across all subgroups (Egger's test, p,0.1), as presented in Table 2 . 
Discussion
The most noteworthy finding of this present study is that in line with the conclusions of most previous studies, [14] [15] [16] [17] [18] [19] [20] our data indicated that low total adiponectin in circulation was a significant risk factor for colorectal cancer. Moreover, for the first time, we pooled data according to adiponectin fractions and found that only non-HMW adiponectin differed significantly between patients with colorectal cancer and controls. We further identified age, gender, smoking, obesity, study design, matching status and sample size as potential sources of heterogeneity. To our knowledge, this is thus far the largest meta-analysis dealing with the relationship of circulating adiponectin and its fractions with colorectal cancer.
The connection between obesity and colorectal cancer is well established, 44, 45 and a great deal of supporting evidence from clinical and epidemiological data has suggested that this connection is probably mediated by abnormal adiponectin in circulation. 46 Adiponectin is the most abundant hormone secreted by adipose tissue, and its anti-inflammatory and insulin-sensitizing properties may, at least in part, expound on the etiologic link between obesity and colorectal cancer. 47, 48 Moreover, accumulating evidence has highlighted a contributory role of adiponectin in anti-carcinogenesis. 49, 50 In vitro studies have showed that adiponectin can promote endothelial apoptosis, repress the maturation and proliferation of colorectal cancer cells and control colony formation, likely through the activation of AMPK-mTOR signaling pathway. 39, 51, 52 Based on the above evidence, it is more reasonable to presume that circulating adiponectin may be involved in the pathophysiological process of colorectal cancer.
Consistent with the findings of major published studies, [14] [15] [16] [17] [18] [19] [20] we confirmed in this present study that low total adiponectin in circulation was a significant risk factor for colorectal cancer. As with most previous meta-analyses, heterogeneity is a serious issue that limits interpretation of effect estimates and requires careful exploration. 53 As a secondary goal of this study, we employed both subgroup analysis and meta-regression analysis to seek possible causes of heterogeneity between studies. In particular, the reduction in total adiponectin was more obvious for CRA and colon cancer, and in studies enrolling subjects of male gender, from East Asia and with normal weight. In addition, the association of total adiponectin with colorectal submit your manuscript | www.dovepress.com
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lu et al cancer was markedly significant in studies with a nested casecontrol design and a large sample size, relative to studies with a retrospective case-control design and a small sample size, indicating the robustness of our observation. Colorectal cancer is a highly heterogeneous disease to which environmental exposure, germ-line susceptibility determinants and accumulated genetic and epigenetic changes contribute interactively. 54 For example, cigarette smoking and alcohol drinking, which are more prevalent in men than in women, are established risk factors for the development and progression of colorectal cancer, 55, 56 which might serve as a possible interpretation for gender-specific difference in adiponectin observed in the present study. Nevertheless, even though we have made great endeavors to seek causes of heterogeneity, there is still strong evidence of heterogeneity in some subgroups, indicating that residual confounding from other sources of heterogeneity in colorectal cancer risk is likely. We agree that further explorations are necessary, and especially analysis of individual participant data could yield further insights.
However, a growing body of research has reported diverse biological activities of different adiponectin fractions, mainly focusing on HMW (insulin sensitivity) and non-HMW (inflammation response) forms. 5, 24 In this context, the sufficient number of eligible studies in this meta-analysis enables us to investigate different adiponectin fractions, and our findings revealed that low non-HMW adiponectin in circulation was a significant risk factor for colorectal cancer and there was no observable significant difference for HMW adiponectin. As previously discussed, non-HMW adiponectin plays a major role in the inflammatory process. 24 Systemic inflammation is a key manifestation of cancer progression and metastasis in many types of cancer including colorectal cancer. 57 We thus develop a further presumption that non-HMW adiponectin may be involved in colorectal carcinogenesis by regulating inflammatory responses. Addressing this presumption is beyond the scope of this meta-analysis, and further experimental studies are required.
Finally, the present study needs to be interpreted cautiously, bearing in mind the following limitations. First, we only retrieved the literature for the papers published in English language, and selection bias cannot be ruled out. Second, all involved studies in this meta-analysis were observational in nature, either cross-sectional or nested, which hindered further causality inference. Third, as discussed above, sources of heterogeneity for a majority of comparisons were not fully accounted for, and additional considerations were necessary. For example, low circulating adiponectin was found to be associated with KRAS-mutant colorectal cancer risk but not with KRAS-wild-type cancer risk. 29 Fourth, only data on circulating plasma/serum adiponectin were summarized, and it is expected that tissue adiponectin concentration in tumor environment may be more relevant to the evaluation of colorectal cancer risk than its circulating concentration. However, data on tissue adiponectin are rarely reported. Fifth, circulating adiponectin concentration was affected by medical treatment or drug intervention, which cannot be taken into account because of lack of data.
In conclusion, through a comprehensive meta-analysis of 7,554 patients with colorectal cancer and 9,798 controls, our data indicate that low total adiponectin, especially its non-HMW fraction, represents a promising risk factor for colorectal cancer. Although there is still residual confounding unaccounted for, we believe that this study can aid in better understanding cancer heterogeneity, highlighting the importance of anti-inflammation therapies to prevent or delay the occurrence of colorectal cancer and thereby providing new insight in its physiology. In addition, further studies are needed to explore underlying mechanisms.
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